newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors

  • PMV Pharma presented updated Phase 2 PYNNACLE trial data for rezatapopt monotherapy at ENA 2026 in Barcelona, Spain.
  • The primary analysis of 65 platinum-resistant/refractory ovarian cancer patients showed a 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response.
  • Across 168 evaluable patients in all cohorts, the ORR was 36% with an 8.1-month median duration of response.
  • Rezatapopt demonstrated efficacy in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.
  • Cohort-specific ORRs included 45% for ovarian cancer, 45% for endometrial cancer, 21% for lung cancer, 21% for other solid tumors, and 17% for breast cancer.
  • A biomarker analysis of 50 patients with available ctDNA data revealed that 90% achieved a ≥50% reduction in TP53 Y220C variant allele frequency within 3-6 weeks.
  • Treatment-related adverse events were mostly Grade 1 or 2, with the most common being nausea, fatigue, increased blood creatinine, vomiting, increased AST/ALT, and anemia.
  • 6% of patients (11 total) discontinued treatment due to treatment-related adverse events.
  • The U.S. FDA granted Fast Track designation for locally advanced or metastatic solid tumors with p53 Y220C mutations and Orphan Drug Designation for TP53 Y220C positive ovarian cancer.
  • PMV Pharma plans to submit a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
Company
PMV Pharmaceuticals, Inc.
Keywords
Nasdaq:PMVP, PMV Pharmaceuticals, Inc.